Artiva Biotherapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Revenue | $0 | $251,000 | $32.9M |
| Operating income | -$89.8M | -$67.3M | -$30.7M |
| Operating expenses | $89.8M | $67.5M | $64.2M |
| Cash from operations | -$76.8M | -$55.0M | -$47.4M |
| Capital expenditure | $2.6M | $642,000 | $3.3M |
| Free cash flow | -$79.3M | -$55.7M | -$50.7M |
| Impairments | $0 | $0 | $0 |
| Total assets | $130.9M | $209.6M | $105.1M |
| Total liabilities | $21.0M | $22.9M | $50.7M |
Shares outstanding 24.7M · Free float 38.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.